Drug discovery startup Insilico Medicine and Italian pharmaceutical company Menarini Group announced their second licensing agreement, which targets unmet needs in oncology with a novel AI-discovered preclinical asset.
The agreement grants Stemline Therapeutics, a subsidiary of Menarini, global rights to develop and commercialize a selective small molecule inhibitor with broad antitumor activity...
